based on 4 analysts
75.00%
Buy
25.00%
Hold
0.00%
Sell
Based on 4 analysts offering long term price targets for Concord Biotech Ltd. An average target of ₹2041.25
Source: S&P Global Market Intelligence
Concord Biotech Ltd price forecast by 4 analysts
Upside of2.51%
High
₹2208
Target
₹2041.25
Low
₹1720
Concord Biotech Ltd target price ₹2041.25, a slight upside of 2.51% compared to current price of ₹2019.3. According to 4 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Concord Biotech Ltd revenue growth forecast
Expected growth rate Q1, FY2026:47.89%
Forecast
Actual
Including amortisation and stock based compensations
Concord Biotech Ltd EPS growth forecast
EPS estimate Q1, FY2026:59.02%
Forecast
Actual
Source: S&P Global Market Intelligence
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | + 8.27 % |
3 Month Return | + 24.56 % |
1 Year Return | + 57.82 % |
Market Stats | |
Previous Close | ₹1,991.20 |
Open | ₹1,992.15 |
Volume | 74.97K |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹20,831.18Cr |
P/E Ratio | 63.54 |
PEG Ratio | 28.36 |
Market Cap | ₹20,831.18 Cr |
P/B Ratio | 10.44 |
EPS | 29.45 |
Dividend Yield | 0.57 |
Sector | Pharmaceuticals |
ROE | 21.63 |
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
BUY | ₹20,831.18 Cr | 22.24% | 0.50 | ₹308 Cr | ₹1,016 Cr | |
BUY | ₹14,767.55 Cr | 100.04% | 0.50 | ₹461 Cr | ₹1,694 Cr | |
NA | ₹315.78 Cr | 42.44% | 0.74 | NA | NA | |
NA | ₹152.88 Cr | 5.23% | 0.60 | NA | NA | |
BUY | ₹13,205.46 Cr | 63.28% | 0.63 | ₹405 Cr | ₹4,506 Cr |
Organisation | Concord Biotech Ltd |
Headquarters | Ahmedabad |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Key events for Concord Biotech Ltd
Concord Biotech Ltd has seen a 6.45% decline over 51 days but reiterated its high-teen revenue growth guidance. The API segment is expected to grow from H2FY25, with top products contributing significantly to revenue. Antique Stock Broking maintains a Buy rating with a revised target price of Rs 2,187.
Concord Biotech Reports Strong Q3 2024 Financials - 13 Nov, 2024
Concord Biotech's standalone net sales for September 2024 reached Rs 310.18 crore, up 18.23% YoY. Net profit rose 16.81% to Rs 98.70 crore, with EBITDA increasing by 15.22%. EPS improved to Rs 9.43 from Rs 8.08 in the previous year.
Concord Biotech Reports Strong Q2 FY25 Earnings - 11 Nov, 2024
Concord Biotech's Q2 FY25 results show an 18.2% YoY revenue increase to ₹310.18 crore and an 18% YoY rise in PAT to ₹95.74 crore, reflecting robust growth.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
FII Holding Up
Foreign Institutions have increased holdings from 7.11% to 8.10% in Sep 2024 quarter
Profit Spike
Netprofit is up for the last 2 quarters, 59.59 Cr → 95.74 Cr (in ₹), with an average increase of 37.8% per quarter
Revenue Rich
Revenue is up for the last 2 quarters, 227.46 Cr → 320.21 Cr (in ₹), with an average increase of 29.0% per quarter
Price Rise
In the last 7 days, CONCORDBIO stock has moved up by 4.0%
Promoter Holding Unchanged
Promoters holdings remained unchanged at 44.08% of holdings in Sep 2024 quarter
MF Holding Down
Mutual Funds have decreased holdings from 5.26% to 4.97% in Sep 2024 quarter
Retail Holding Down
Retail Investor have decreased holdings from 38.41% to 37.93% in Sep 2024 quarter
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 44.08% | 0.00 | |
Foreign Institutions | 8.1% | 13.93 | |
Mutual Funds | 4.97% | ||
Retail Investors | 37.93% | ||
Others | 4.92% |
Concord Biotech Ltd in the last 5 years
Lowest (36.27x)
October 4, 2023
Industry (54.82x)
November 21, 2024
Today (63.54x)
November 21, 2024
Highest (86.91x)
September 20, 2024
Concord Biotech Ltd’s net profit jumped 18.17% since last year same period to ₹95.74Cr in the Q2 2024-2025. On a quarterly growth basis, Concord Biotech Ltd has generated 60.66% jump in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending March 2024, Concord Biotech Ltd has declared dividend of ₹8.75 - translating a dividend yield of 0.43%.
Read More about DividendsBearish
Neutral
Bullish
Concord Biotech Ltd is currently in a Bullish trading position according to technical analysis indicators.
Concord Biotech Ltd (CONCORDBIO) share price today is ₹2019.3
Concord Biotech Ltd is listed on NSE
Concord Biotech Ltd is listed on BSE
PE Ratio of Concord Biotech Ltd is 63.54
PE ratio = Concord Biotech Ltd Market price per share / Concord Biotech Ltd Earnings per share
Today’s traded volume of Concord Biotech Ltd(CONCORDBIO) is 74.97K.
Today’s market capitalisation of Concord Biotech Ltd(CONCORDBIO) is ₹20831.18Cr.
Concord Biotech Ltd(CONCORDBIO | Price |
---|---|
52 Week High | ₹2664 |
52 Week Low | ₹1205.45 |
Concord Biotech Ltd(CONCORDBIO) share price is ₹2019.3. It is down -24.20% from its 52 Week High price of ₹2664
Concord Biotech Ltd(CONCORDBIO) share price is ₹2019.3. It is up 67.51% from its 52 Week Low price of ₹1205.45
Concord Biotech Ltd(CONCORDBIO | Returns |
---|---|
1 Day Returns | 28.1% |
1 Month Returns | 8.27% |
3 Month Returns | 24.56% |
1 Year Returns | 57.82% |